Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.50 |
| ▸ | MEN1 | O00255 | 4/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | ACP3 | P15309 | 1/20 | 0.50 |
| ▸ | GRM8 | O00222 | 1/20 | 0.50 |
| ▸ | GRM6 | O15303 | 1/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.50 |
| ▸ | DRD3 | P35462 | 1/20 | 0.50 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.50 |
| ▸ | GRM1 | Q13255 | 5/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | HPGD | P15428 | 4/20 | 0.47 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.47 |
| ▸ | PARP1 | P09874 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28243743 | 1.00 | HSD17B10 (0.50) | HSD17B10TDP1MEN1KMT2ACYP2C9 | |
| SCHEMBL5293096 | 1.00 | HSD17B10 (0.50) | HSD17B10TDP1MEN1KMT2ACYP2C9 | |
| Hydrochloric Acid SCHEMBL19717652 | 0.98 | HSD17B10 (0.49) | HSD17B10TDP1MEN1KMT2ACYP2C9 | |
| Hydrochloric Acid SCHEMBL28764410 | 0.98 | HSD17B10 (0.49) | HSD17B10TDP1MEN1KMT2ACYP2C9 | |
| SCHEMBL1352192 | 0.85 | PARP1 (0.50) | HSD17B10TDP1ACP3PARP1CYP1A2 | |
| SCHEMBL20844696 | 0.85 | PARP1 (0.50) | HSD17B10TDP1ACP3PARP1CYP1A2 | |
| SCHEMBL1352191 | 0.85 | PARP1 (0.50) | HSD17B10TDP1ACP3PARP1CYP1A2 | |
| Hydrochloric Acid SCHEMBL28755174 | 0.83 | PARP1 (0.48) | HSD17B10TDP1ACP3PARP1 | |
| SCHEMBL10956210 | 0.83 | PARP1 (0.46) | HSD17B10TDP1MEN1KMT2ACYP2C9 | |
| SCHEMBL6120391 | 0.83 | CYP2C19 (0.52) | HSD17B10TDP1MEN1KMT2ACYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159538-A1 | PYRROLIDINE-PYRAZOLES AS PYRUVATE KINASE ACTIVATORS | GLOBAL BLOOD THERAPEUTICS, INC. | 2023-05-25 | — | — | US | disclosed |
| EP-4126876-A1 | PYRROLIDINE-PYRAZOLES AS PYRUVATE KINASE ACTIVATORS | Global Blood Therapeutics, Inc. (US) | 2023-02-08 | — | — | EP | disclosed |
| WO-2021202796-A1 | PYRROLIDINE-PYRAZOLES AS PYRUVATE KINASE ACTIVATORS | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2021-10-07 | — | — | WO | disclosed |
| US-20200123132-A1 | ANTIVIRAL COMPOUNDS | GILEAD PHARMASSET LLC | 2020-04-23 | — | — | US | disclosed |
| US-10344019-B2 | Antiviral compounds | GILEAD PHARMASSET LLC (US) | 2019-07-09 | — | — | US | disclosed |
| EP-3284741-A1 | ANTIVIRAL COMPOUNDS | Gilead Pharmasset LLC (US) | 2018-02-21 | — | — | EP | disclosed |
| EP-2640719-B1 | ANTIVIRAL COMPOUNDS | GILEAD PHARMASSET LLC (US) | 2017-05-10 | — | — | EP | disclosed |
| US-20150353529-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2015-12-10 | — | — | US | disclosed |
| US-20150353529-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2015-12-10 | — | — | US | disclosed |
| US-9156823-B2 | Antiviral compounds | GILEAD PHARMASSET LLC (US) | 2015-10-13 | — | — | US | disclosed |
| US-9156823-B2 | Antiviral compounds | GILEAD PHARMASSET LLC (US) | 2015-10-13 | — | — | US | disclosed |
| US-20140018313-A1 | ANTIVIRAL COMPOUNDS | Gelead Sciences, Inc. | 2014-01-16 | — | — | US | disclosed |
| US-20140018313-A1 | ANTIVIRAL COMPOUNDS | Gelead Sciences, Inc. | 2014-01-16 | — | — | US | disclosed |
| WO-2012068234-A2 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2012-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140018313-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | HSD17B10 3314/4885TDP1 1330/4885MEN1 4292/4885 |
| US-10344019-B2 | Antiviral compounds | MAVS, EIF2AK2, ZC3HAV1 | HSD17B10 3314/4885TDP1 1330/4885MEN1 4292/4885 |
| US-20150353529-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | HSD17B10 3314/4885TDP1 1330/4885MEN1 4292/4885 |
| US-20200123132-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | HSD17B10 3314/4885TDP1 1330/4885MEN1 4292/4885 |
| US-20230159538-A1 | PYRROLIDINE-PYRAZOLES AS PYRUVATE KINASE ACTIVATORS | PDK1, PDK2, PKM | HSD17B10 2914/4885TDP1 1098/4885MEN1 4414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.